KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Deferred Revenue (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Current Deferred Revenue for 6 consecutive years, with $15.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue rose 14.69% year-over-year to $15.7 million, compared with a TTM value of $15.7 million through Sep 2025, up 14.69%, and an annual FY2024 reading of $19.2 million, down 29.21% over the prior year.
  • Current Deferred Revenue was $15.7 million for Q3 2025 at AbCellera Biologics, down from $16.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $37.2 million in Q1 2023 and bottomed at $13.7 million in Q3 2024.
  • Average Current Deferred Revenue over 5 years is $26.2 million, with a median of $30.9 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue soared 89.88% in 2023, then crashed 60.36% in 2024.
  • Year by year, Current Deferred Revenue stood at $20.5 million in 2021, then plummeted by 30.24% to $14.3 million in 2022, then soared by 89.88% to $27.2 million in 2023, then decreased by 29.21% to $19.2 million in 2024, then fell by 18.39% to $15.7 million in 2025.
  • Business Quant data shows Current Deferred Revenue for ABCL at $15.7 million in Q3 2025, $16.9 million in Q2 2025, and $32.5 million in Q1 2025.